WO2016079204A1

WO2016079204A1 - Multifunctional capsular implant

Info

Publication number: WO2016079204A1
Application number: PCT/EP2015/077015
Authority: WO
Inventors: Pierre Coulon; Alexis MATHIEU
Original assignee: Pierre Coulon; Mathieu Alexis
Priority date: 2014-11-18
Filing date: 2015-11-18
Publication date: 2016-05-26
Also published as: FR3028410A1

Abstract

The present invention concerns a capsular implant (1), characterised in that it comprises a filiform body (6) comprising a plurality of contiguous segments, the filiform body (6) having a peripheral surface (5) that defines at least one outer arc of a circle (x) along the filiform body (6) and at least one inner arc of a circle (y) along the filiform body (6), the filiform body (6) comprising at least one open and non-closed chamber (2) of an active formulation and/or of an analysis or measuring device and/or of a device for controlling the release of (an) active ingredient(s), said open and non-closed chamber (2) being disposed on the peripheral surface (5) of said filiform body (6) along said inner arc of a circle (y) and allowing direct contact between said formulation and/or said device(s) and the capsular medium. It also concerns the use of said capsular implant (1) in the context of post-operative care following surgery of the lens in humans or animals.

Description

Multifunctional capsular implant

The present invention relates to the field of ophthalmology. In particular, it relates to circular capsular implants, circular open, semicircular or pseudo circular having a possibility of release of principle (s) active (s) active in the eye, and / or incorporation of devices for analysis or measurement.

Ophthalmic surgery and the administration of active ingredients in it pose a number of problems, due to the difficulty of access to the interior of the eye, the frequency of instillation of eye drops, and the meticulousness required by certain manipulations. In addition, there are many problems raised by the release itself and its mechanical support which must respect both the current data of science and good surgical practices.

[0003] In the field of ophthalmic surgery, lens surgery has an important place. It consists mainly of two types of surgery:

cataract lens surgery;

- clear lens surgery.

[0004] The first type of lens surgery is cataractous lens surgery.

Cataract is a disease that is characterized by the partial or total opacification of the lens, natural converging lens located inside the eye, and more specifically within an envelope called capsular bag. This opacification is responsible for a gradual decline in vision, all the more important as opacification is important.

Cataract is by far the most common cause of blindness worldwide. Indeed, more than 10% of the world's population over 65 is affected, as well as 60% of the world's population over 85 years of age. The prevalence increases with age.

Cataract is found in nearly 40% of the 37 million blind people in the world, and according to WHO standards, there are 20 million blind individuals due to bilateral cataract. It is therefore a major public health problem, and even if the treatment is known and reliable, its application is limited, in particular, by problems of cost, competence, accessibility and post-treatment options. procedure.

The main contributing factors are the following: malnutrition, dehydration, exposure to the sun, poor living conditions, factors genetic, etc. When these risk factors are present, cataracts can occur in a relatively young population, as is the case in some developing countries.

[0009] The global situation is of sufficient concern for cataract treatment programs for entire populations to be organized. In particular, we can cite the initiative of Dr. Sanduk Ruit, a Nepalese surgeon, who withdrew more than 1,400 cataracts during an Indonesian program. Similar programs exist for other needy states, such as India, Pakistan, Nepal. These programs are mainly organized in countries where, in addition to the aforementioned factors, there are genetic factors that explain the number of cataracts. Cataract surgery is then performed on a large scale by surgeons who sometimes perform up to 6000 to 7000 cataracts / year. Under these conditions, it is difficult to have satisfactory postoperative management.

[00010] Usually, cataract therapy includes surgery and a demanding post-operative management, particularly involving the administration of eye drops and nursing care.

If cataract is mainly considered a human pathology, a number of animals also suffer.

The animal therapy also has certain additional constraints of cost and adaptability of the devices. Indeed, most of the time, no health insurance is underwritten for the animals, and the entire treatment is the responsibility of the master / breeder. In addition, more specifically concerning cataract therapy, post-operative cataract treatments are particularly difficult to administer to animals. By way of example, this type of medicinal treatment may consist of the instillation of eye drops 3 times a day for 30 to 45 days, which can constitute a considerable loss of time for the master / breeder.

[00013] Finally, the diversity of animal morphologies is a constraint. Each implant will indeed have a geometry adapted to the capsular bag of the animals concerned.

[00014] The second type of lens surgery is clear lens surgery.

It consists of the removal of a non-cataracted lens, the purpose of this removal is to improve certain vision disorders affecting the view of the patient concerned.

In practice, clear lens surgery is an effective and precise option for the correction of certain severe myopia, or certain hyperopia difficult or impossible to correct, or some presbyties.

At present, clear lens surgery is limited because of the benefit / risk ratio of such surgery. This limitation is most often related to the age of the patient and the severity of his condition. In practice, it is often performed in elderly patients with relatively severe eye problems.

[00018] Nevertheless, this surgery is brought to evolve, because of surer and safer surgical practices.

[00019] Therapy including lens surgery (cataract or clear as appropriate), in the absence of complications, includes:

lens surgery ("the operation of cataract / clear lens"); during this procedure, the lens (cataract or clear as appropriate) is removed by destruction-aspiration and then replaced by an optical lens or optical implant, and

a cumbersome postoperative management; postoperative management consists of postoperative polytherapy mainly based on antibiotics, steroidal anti-inflammatory drugs (steroids) and non-steroids, as well as nursing care dependent on autonomy and skill of the operated person.

According to the recommendations of the various colleges of ophthalmology, the post-operative management in humans may consist of:

an antibiotic injected at the end of the procedure (for example cefuroxime);

- eye drops (antibiotic one drop three to four times a day for ten days, steroids and nonsteroidal anti-inflammatory drugs one drop three times a day for at least one month);

many nursing care (3 times a day for about 1 month).

To this is added the management of the side effects of eye drops, a potential non-compliance of these treatments that can give infections with dramatic consequences.

[00022] For example, eye drops may have the side effects of causing dry eye, conjunctival irritation, allergies.

[00023] These side effects are an unnecessary consultation reason found in the follow-up of almost 100% of the patients having undergone lens surgery. For all these reasons, the post-operative care is today too expensive and very demanding compared to the price and ergonomics of the surgery itself.

Other blatant disadvantages are caused by the use of eye drops. In particular, it is very difficult to determine the amount of active ingredient administered, insofar as it depends on the quantity administered (difficulties related to the dosage, the quantity of the active ingredients administered is not controlled as it should be) and possible losses (passage of eye barriers, loss of product during administration).

In the medium term, after a lens surgery (cataract or clear), the patient very often develops a secondary cataract. It corresponds to opacification of the capsular bag. Indeed, some cells of the periphery of the bag migrate to the center of the visual axis. This cell migration is responsible for a decrease in postoperative visual acuity by opacification of the posterior capsule and by diffraction of light. This secondary opacification of the posterior capsule called capsulose is especially treated by YAG laser.

Finally, YAG laser therapy has a number of side effects: ocular inflammation, increased ocular tension, photophobia, increased risk of Iatrogenic retinal detachment, etc.

Very great progress has been made in the field of lens surgery in recent decades: a 12 mm incision, specialists have moved to incisions of only 2 mm or less.

In general, the incisions practiced in ophthalmic surgery are smaller and smaller. Intraocular implants (lenses, capsular rings) must be capable of being inserted into such openings. They can be injected through an injector whose diameter is adapted to the size of the incision, or even arranged by the surgeon using various surgical instruments.

Despite the rapid evolution of the surgical technique, no major breakthrough has been observed in the post-operative management.

[00031] Veterinary cataract surgery has also benefited from technological advances in humans.

The lens is surrounded by an envelope called "capsular bag" ultrafine membrane (elastic part) which helps control its shape when the eye focuses on objects located at different distances. The capsular bag therefore plays a fundamental role in accommodation processes under normal physiological conditions. During a lens surgery, the capsular bag must be opened in a circular manner (capsulorhexis) so that the surgeon can access the lens.

It is crucial that its integrity be maintained, this notably preventing the migration of fragments of the crystalline lens into the vitreous and then onto the retina.

The integrity of the capsular bag also makes it possible to correctly position the optical implant in its most physiological position possible. If the capsular bag is broken during surgery, the postoperative management becomes even more cumbersome and more delicate.

In the longer term, the integrity of the capsular bag allows the positional stability of the optical implant and therefore of the refraction: a migration, even a minor one, of the optical implant forwards or backwards can generate major visual disturbances and very disabling for the patient.

In summary, the capsular bag has a very important role in the preservation of the physio-mechanical balance of the eye (respect for the integrity of the blood-aqueous barrier). This balance is, among other things, ensuring the proper positioning of the intraocular optical implant and its good stability over time.

[00038] Today, as part of the therapy including a crystalline lens surgery (cataract or clear depending on the case), a need to have new solutions for simplified postoperative management and avoiding any risk of complications. infection (desired goal: zero infection).

In particular, there is a need for solutions allowing the provision of active ingredients, as well as other devices, directly in the capsular bag.

These solutions must not only allow a simplified care (especially by the removal of eye drops and therefore nursing), but also have other advantages, in particular the ability to control the amount of active ingredient, the possibility of adding other active ingredients having other particular effects, as well as the possible integration of other devices, for example analysis and / or measurement devices and / or a device for controlling the release of active principle (s).

[00041] With regard to the administration of active principles, a number of solutions are known from the prior art.

Some devices are intended to allow the diffusion of active ingredients inside the eye, especially in the vitreous body.

Such implants are described in WO 02/43785, WO 02/02076, WO 04/026106 and WO 04/062649. Other applications on behalf of ALLERGAN relatively close to those previously mentioned can also be reported: WO 2005/105046, WO 2005/110362, WO 2005/107127, WO 2005/110436 or else WO 2008/070402. Another application, on behalf of OCULEX, can also be reported: WO 95/13765.

These applications describe intravitreous implants with prolonged effect whose specialty OZURDEX® is an illustration. It is particularly indicated for the treatment of adult patients with macular edema following retinal venous occlusion or central retinal vein occlusion. The granule thus implanted moves in the vitreous body, which can cause disturbances of the vision passengers simply due to its passage in the visual axis.

Other intra-vitreous implants are available on the market, such as the specialty ILUVIEN®, corresponding to the application WO 2011/079123 in the name of ALIMERA SCIENCE, INC.

Other devices for releasing active ingredients have been described in the following applications / patents:

EP 0 322 319 in the name of OCULEX discloses implants for insertion into the posterior or anterior chamber of the eye. The application WO 2006/057859 in the name of THERAKINE discloses an ocular implant, unspecified concerning its implantation area. The application WO 2010/093945 in the name of GLAUKOS CORPORATION discloses implants intended to be implanted in the uveoscleral zone. The application EP 0 544 948 in the name of UNIVERSITY OF MIAMI discloses implants intended in particular to be implanted in the vitreous body.

[00048] Moreover, certain devices that can be recharged by invasive procedures have also been described.

This is particularly the case in the application WO 1993/03686 in the name of CUMMING, wherein a releasable capsule implanted intraocularly can / must be reloaded. The release times of the capsule are not specified, probably because they are relatively short, hence also the need to recharge, which is problematic in terms of infection, ergonomic treatment etc.

The application WO 2010/088548 in the name of FORSIGHT LABS INC. discloses a rechargeable implant by a semi-invasive procedure, the implant is inserted into the sclera.

The application WO 2009/140246 in the name of UNIVERSITY OF UTAH also has a device with a re-filling valve.

These rechargeable devices by invasive procedures are not satisfactory, just by the existence of such invasive procedures, having a number of drawbacks: reduced ergonomics of taking into account load, increased cost of care, possibility of creating a microbial entry door.

As regards the diffusion and release methods, it has been proposed that active principles be diffused through hemipermeable membranes, this being particularly the case in the previously cited applications WO 2009/140246 in the name of UNIVERSITY OF UTAH and WO 2006/057859 in the name of THERAKINE. In the case of the patent application WO 2009/140246, it is a hemipermeable film in PES glued to the body of the implant to close a chamber in which the active ingredient has been introduced. This room is not, therefore, open, but on the contrary, closed.

The hemipermeable membranes are obviously not a good solution: little adaptability to any pharmaceutical active principle, risk of rupture, design difficulties, variable contact surface and difficult to control, etc.

Some teams have also worked on devices for the diffusion of active principles with multilayer systems and / or coatings.

In the application WO 03/061625 in the name of SNYDER & DOBRUSIN, it is presented an ophthalmic implant including pharmaceutical molecules intended to be salted out of the implant. Whatever the embodiments, the active agent is located, at least in part, in a lower layer than another layer that is bioerodible. This multilayer system has a great disadvantage: multiplication of components of different nature, which can cause problematic erosions (separation of layers, etc.). In addition, these devices are relatively difficult to formulate. In the case of this application, any detachment of one or more releasing layers may be particularly dangerous, due to the sudden and massive release of pharmaceutical active principle in the eye (sudden increase of the contact surface) .

[00057] Other futile approaches of this type are presented in other applications. In the application WO 2010/011585 in the name of ALCON, an ocular device releasing from a coating layer is described. In the application WO 2012/106413 in the name of ABBOTT, a method of coating a lens by adhesion, impregnation, etc. is described. In the application WO 2005/110364 in the name of ALLERGAN, a multilayer release device is also described. In the application US 2012/213841 in the name of NOVARTIS, an intraocular biodegradable implant coated with a pharmaceutical active principle is described. Finally, in the application WO 2004/016298 in the name of SCIMED LIFE SYSTEMS INC., Multilayer systems are also described. All these solutions are extremely difficult to put into practice and / or are surgically unsuited to the current practices of lens surgery and / or are not very adaptable to several active ingredients, and / or require expensive developments, etc.

[00059] Probably in the face of the effective inapplicability of the multilayer / coating systems, some teams have worked on extremely complex release technologies.

An example of this type of technology is presented in US Patent 6,444,217 in the name of UNIVERSITY OF WASHINGTON: a system for releasing active agent from an implant is presented. The active agent molecules are included in an entanglement of C10-C22 surface chains located on the surface of the implant. A stimulus (sound or heat for example) allows the release of active molecules by the organization / disorganization of C10-C22 chains. A similar system is described in WO 2008/113043 in the name of the same applicant.

These systems are particularly complex, and therefore difficult to adapt to different active ingredients.

[00062] Finally, certain approaches have been directed to complex structures presented as implantable in the eye.

[00063] To cite only one request, it is a question in the WO application

2013/096626 in the name of ABBOTT MEDICAL OPTICS INC., An ophthalmic implant in the form of "bone structure". This frame can be in the form of cylindrical grid, springs etc. (Figures 4 and 5).

This solution is not satisfactory just from the point of view of implantability, and the framework is obviously not implantable in the capsular bag in minimal incision conditions.

With regard to implants intended to be integrated into the capsular bag, two main types can be mentioned: intraocular lenses and capsular rings.

Intraocular lenses are devices intended to replace the lens (cataract or clear as appropriate), they are inserted into the capsular bag during lens surgery. They have optical properties allowing them to replace those of a normal lens.

In the prior art, some teams have focused their research on releasing lenses and having the appropriate optical properties.

This is particularly apparent from the application WO 2007/112946 in the name of UNIVERSITES GENEVA AND LAUSANNE and the application WO 97/06838 in the name of MASSACHUSETTS EYE & EAR INFIRMARY. In general, given the mechanical constraints imposed on the lenses during their insertion through narrow orifices (especially in recent years due to the very significant reduction in the size of the incision), it seems difficult to to load active ingredients. Indeed, any "body" integrated in the thickness of the lens would be crushed or expelled. Thus, the lenses can be adapted only to a single coating (for example with heparin, or other pharmaceutical active ingredient) but can not under any circumstances release at the same time several active ingredients.

In addition, the lenses are processed for their optical properties and the preservation of these properties is often incompatible with the diffusion devices which imply a necessary erosion or evolution of the materials.

[00071] In order to prevent retraction of the capsular bag and contraction of capsulorhexis (capsulo-phimosis), capsular rings are widely used.

The capsular ring can be inserted during the lens surgery (cataract or clear) in the capsular bag. It avoids the retraction of the latter.

[00073] A number of terms are commonly used to designate a capsular ring: "capsular tension ring", "capsular equatorial ring", "tension ring", etc.

In the prior art, some teams have worked on capsular rings having particular properties including administering active ingredients.

[00075] Patent EP 1 696 832 in the name of MORCH ER GmbH discloses a capsular ring having rigid segments made from acrylate as well as softer segments made from hydrophilic flexible copolymers H EMA / PM MA. The ring shown in particular in the figures appears as immovable in minimal incision conditions, in that it is not open. The invention focuses on the apparently advantageous deployment of the capsular ring within the capsular bag. It is specified that the flexible segments can be "judiciously impregnated" with a pharmaceutical active principle, but no other precision is given on the inclusion / diffusion mode.

[00076] Other approaches in which the mechanical considerations are preponderant exist. In the application WO 2007/112946 in the name of INSIGHT IN NOVATION is disclosed a mechanical barrier system for cell migration. In the application WO 98/15238 in the name of CORN EAL, it is perceived as imperative to use non-biodegradable release systems because the mechanical considerations are perceived as higher conditions. This last request illustrates in particular the difficulties that exist in reconciling the release and satisfactory mechanical properties. In the application WO 2001/35868 in the name of COR EAL, a particular form of capsular ring is presented, this form allows a better introduction into the injection system. In the application WO 2004/069101 in the name of IOL-TECHNOLOGIE-PRODUCTION, a mechanically acting anti-opacification capsular ring is described. In the application WO 2011/151839 in the name of MIRLAY, an optical system having an improved alignment is presented.

The publication by B.Cochener (Journal Français d'Ophtalmologie, Vol 26, No. 3 - March 2003, pp. 223-231) describes a non-biodegradable capsular ring based on HPMA / MMA 75-25 copolymer releasing 5-FU for prevention of secondary cataract). The properties of the HPMA / MMA copolymer, and in particular its lipophilicity, allow the incorporation, within the material, of a particular pharmaceutical active ingredient, 5-FU, to fight against secondary cataracts. The only compound included is 5-FU.

In the application WO 2014/058965 in the name of ALCON, it is presented an implant intended to be inserted into the eye, including a structure having haptics. On the circular structure, an intraocular pressure sensor and an antenna are used especially in the context of the management of glaucoma. The implant has a relatively complex structure, and must be inserted with a particular device, as shown in Figures 8, 9 and 10.

In addition to the treatment of cataracts, the capsular rings may have other uses, in particular the replacement of the capsular bag when the latter no longer exists: some rings have been designed to mechanically support the optical implant, these rings. can be sutured to the sclera. These are rather special capsular rings.

In summary, as regards the prior art, it appears that the prior art does not disclose implants for the administration of active ingredients within the capsular bag and which are implantable in a simple surgical procedure. with a minimal incision.

There remains a need for a capsular implant having the following characteristics: 1) from the surgical point of view: the capsular implant is likely to be inserted after a minimum incision, corresponding to current and future good surgical practice for example about 2 mm, or less; it must not have any roughness or projection relative to the surface of the implant.

2) from a mechanical point of view: the capsular implant is likely to have mechanical characteristics conciliating a necessary rigidity and flexibility allowing insertion and easy positioning, whether by clamp or injector. Moreover, the mechanical properties must evolve as little as possible over time, or even not evolve at all. In addition, its mechanical properties must be adapted to the capsular environment and respect the integrity of the walls of the capsular bag and may also, in some cases, allow the stabilization of the walls of the capsular bag;

3) from the point of view of pharmaceutical active principles administration: the capsular implant is likely to allow the administration of one or more active principle (s), mainly in the capsular bag and / or in the anterior chamber these active principles, as well as their number, must be adaptable to a given patient, according to its physiological characteristics, its pathology (s). The kinetics of delivery must be independently adjustable for each active ingredient;

4) from the point of view of manufacture: the capsular implant is likely to have a relatively simple design, in order to be adapted to the widest variety of active ingredient, or even existing compositions on the market;

5) from the economic point of view: the capsular implant is likely to have a manufacturing cost compatible with its use in the mass operations of populations that do not have access to expensive treatments. It must also be adaptable to animals, with minimal adaptations;

6) from the point of view of public health: the use of the capsular implant is likely to have the direct consequence of reducing the incidence of post-operative complications; 7) from the point of view of scalability: the capsular implant is likely to have an ability to adapt to new technologies (which can result in particular from the miniaturization of existing technologies) that can be associated with it;

8) from the point of view of adaptability: the capsular implant is likely to be adaptable to a given patient. Thus, the post-operative treatment may vary from one individual to another, depending on possible allergies to one or more active principle (s), or even needs of particular classes of additional active ingredients ( anticancer, etc.), varying dosages, etc., in summary, the capsular implant must present a possibility of "therapeutic customization". [00082] Surprisingly, a capsular implant having all the advantages mentioned could be achieved.

The object of the invention is a capsular implant, characterized in that it comprises a filiform body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circular arc along of the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one fixing means, said fixing means being an open and non-closed chamber disposed on the peripheral surface of said filiform body along of said inner circular arc or in one of the free ends of said implant.

The object of the invention is a capsular implant, characterized in that it comprises a filiform body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circular arc along of the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one open and unclosed chamber disposed on the peripheral surface of said filiform body along said inner circular arc or in one of the free ends said implant.

The object of the invention is a capsular implant, characterized in that it comprises a filiform body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circular arc along of the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one means for fixing an active formulation and / or a device for analyzing or measuring and / or a device for controlling the release of active principle (s), said fixing means being an open and non-closed chamber disposed on the peripheral surface of said filiform body along said inner circle arc or in one of the free ends of said implant.

The object of the invention is a capsular implant, characterized in that it comprises a filiform body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circular arc along of the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one means for fixing an active formulation and / or an analysis or measurement device and / or a device for controlling the release of active principle (s), said fixing means being an open and non-closed chamber disposed on the peripheral surface of said filiform body along said inner circle arc or in one of the free ends said implant and allowing direct contact between said formulation and / or said device (s) and the capsular medium.

In one embodiment, the implant has neither roughness nor protrusion with respect to the surface of the implant.

In one embodiment, the invention is a capsular implant, characterized in that it comprises a filamentary body comprising a plurality of contiguous segments, the filiform body having a peripheral surface which defines at least one outer circular arc. along the filiform body and at least one inner circular arc along the filiform body, the filiform body comprising at least one attachment means of an active formulation, said fixing means being an open and non-closed chamber disposed on the peripheral surface of said filamentary body along said inner circular arc in one of the free ends of said implant.

The capsular implant object of the invention is adapted to the capsular environment and respects the integrity of the walls of the capsular bag. It may also, in some cases, allow the stabilization of the walls of the capsular bag.

From the surgical point of view, the capsular implant according to the invention can be inserted with the most modern surgical methods providing for a minimum incision, of the order of 2 mm, or even less (1.8 mm, 1, 6 mm, etc.). In particular, it can be inserted with a commonly used injector, in which it can notably be unfolded and momentarily present a substantially rectilinear shape. The capsular implant may also be inserted by the surgeon with forceps and / or any other ophthalmic surgical instrument. Its surface does not have asperities or roughness / irregularities limiting its "sliding" (its implantation in the capsular bag - respect for fragility on capsular bag) in the ocular tissues. Then, from the point of view of the delivery of active principles, it appears that the capsular implant object of the invention can be "loaded" into different active formulations easily prior to the packaging of the implant ( in a manufacturing plant, etc.) and / or by the introduction of an active formulation by the surgeon directly before or even during the surgical procedure. A polytherapy can thus be achieved by means of several active formulations. The capsular implant that is the subject of the invention can also be adapted for use in animal ophthalmology, as well as in experimental ophthalmology.

From the point of view of manufacture, the capsular implant according to the invention has a limited number of components. In particular, a single component can be used for the realization of the capsular implant, or only a limited number of components, to which will be added other components related to active formulations or other devices.

From the economic point of view, the simplicity of the capsular implant object of the invention has a real interest in its manufacture which is also easy to implement. In addition, the post-operative treatment can be made much less expensive, and more easily achievable because the concepts of daily treatment and several times a day become obsolete. In addition to the disappearance of the difficulties related to the observance, the problem related to the septic conservation of the open eyedrops disappears (hot countries, developing countries). Thus the capsular implant becomes applicable to the greatest number.

Finally, from a mechanical point of view, the capsular implant object of the invention has no disadvantage compared to a conventional capsular ring. Its diameter is not greater, its surface has no roughness or roughness / irregularity limiting its "sliding" in ocular tissues, its manipulation is not more delicate (does not question the codes of good collegially and academically accepted surgical practices), its ability to be disposed of in a possible setting device is retained. The absence of roughness or roughness / irregularity allows compliance once in place of the walls of the capsular bag. With respect to its strength, although material may have been removed from the implant, its mechanical strength is not impaired.

The active ingredients used in the active formulations that can be attached to the capsular implant object of the invention are numerous, it is about any asset of interest.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be selected from the group of antibiotics, anti-inflammatories, anti-glaucoma drugs, anti-cancer drugs, active ingredients used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active ingredient that can be used to treat a pathology of the eye (retinopathies, uveitis, various infections of the eye).

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of antibiotics. Some examples of usable antibiotics are given below: tetracyclines (daunomycin, tetracycline, chloretetracycline, oxytetracycline, etc.), glycopeptides (vancomycin, etc.), aminoglycosides (gentamycin, etc.), aminosides (tobramycin, neomycin, etc.). ), fluoroquinolones (ciprofloxacin, moxifloxacin, etc.), quinolones (gatifloxacin, etc.), polypeptides (bacitracin, polymyxin, etc.), phenicolates (chloramphenicol, etc.), macrolides (erythromycin, etc.), sulfonamides (sulfacetamide, sulfamethoxazole, sulfisoxazole, etc.), and any other antibiotic. The preferred antibiotics are those belonging to the quinolone and cephalosporin classes. As regards quinolones, they may be first generation quinolones (nalidixic acid, oxolinic acid, pipemidic acid, piromidic acid, cinoxacin, flumequine, rosoxacin, etc.), second generation (balofloxacin, gepeploxacin, levofloxacin, pazufloxacin, sparfloxacin, temafloxacin, tosufloxacin, etc.), or third generation (clinafloxacin, garenoxacin, gemifloxacin, moxifloxacin, gatifloxacin, sitafloxacin, trovafloxacin, prulifloxacin, etc.). The active ingredients belonging to the particularly preferred quinolone family are ofloxacin and norfloxacin. Cephalosporins may be first-generation cephalosporins (cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotine, cefapirine, cefatrizine, cefazaflure, cefazedone, cefazolin, cefradine, cefroxadine, cefezole, cefaclor, etc.) second generation (cefamandole, cefuroxime, cefonicid, ceforanid, cefprozil, loracarbef, cefotetan, cefoxitin, etc.), third generation (cefotiam hexetil, ceftriaxone, cefotaxime, ceftizoxime, ceftazidime, cefoperazone, cefsulodine, ceftibuten, cefixime, cefatamet, cefpodoxime, etc.) or even extended spectrum (cefepime, cefpriome, etc.).

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of anti-inflammatory, steroidal (AIS) and / or non-steroidal (NSAID) drugs. . Some examples of AIS are given below: triamcinolone, dexamethasone, prednisolone, hydrocortisone, corticosterone, fluocinolone, prednisolone, methylprednisolone, fluorometholone, betamethasone, tetrahydrocortisol, rimexolone, etc. Some examples of NSAIDs are given below: indomethacin, nepafenac, diclofenac, bromfenac, ketorolac, suprofen, etc.

[00099] Anti-inflammatories and antibiotics may especially be used as part of the post-operative management of lens surgery.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of active ingredients used in the treatment of glaucoma, a certain number of active principles can be used, a non-limiting list is given below: beta-blockers (timolol, betaxolol, levobetaxolol, cardolol, atenolol, metipranolol, etc.), prostaglandin analogues (latanoprost, bimatroprost, travoprost, unoprostone, etc.), agonists of alpha-adrenergic receptors (brimonidine, apraclonidine, etc.), ephinephrine and its derivatives, such as dipiverine hydrochloride, calcium antagonists (nimodipine, etc.), carbonic anhydrase inhibitors (acetazolamide, brinzolamide, dorzolamide, methazolamide , dichlorophenamide, etc.), miotics (pilocarpine, acetylcholine, isoflurophate, demecarium bromide, echothiophate iodide, phosphol iodide ine, carbachol, physostigmine, etc. ).

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of anticancer agents. A non-limiting list is given below: 5-fluorophore uracil, methotrexate, adriamycin, tamoxifen, actinomycin, angiopeptin, avastine, mitotoxin, mitomycin, colchicine, daunomicin, etc.

[000102] The anti-cancer drugs may especially be used as part of the prevention / treatment of secondary cataracts.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of active principles used in the treatment of AMD. A non-limiting list is given. hereafter: VEGF inhibitors (ranibizumab, pegaptanib or even afiibercept), anti-TGF-beta agents, integrin a5b1 antagonist, rapamycin, PDGF inhibitors, integrin inhibitors, various anti-angiogenesis agents, etc.

The active ingredients that can be used in the active formulations which can be attached to the capsular implant which is the subject of the invention can be chosen from the group of immunosuppressants. A non-limiting list is given below: dexamethasone, betamethasone, etc. The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of antivirals. A non-limiting list is given below: ganciclovir, trifluorothymidine, aciclovir, DDI, AZT, foscarnet, vidarabine, trifluorouridine, idoxuridine, ribavirin, protease inhibitors, anti-cytomegalovirus agent, etc.

The active ingredients that can be used in the active formulations which can be attached to the capsular implant which is the subject of the invention can be chosen from the group of antifungal agents. A non-limiting list is given below: fluconazole, nitrofurazone, amphotericin B, ketoconazole, etc.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of antiallergics, a nonlimiting list is given below: methapyriline, chlorpheniramine, pyrilamine, prophenpyridamine, etc.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of anesthetics, a nonlimiting list is given below: lidocaine, mepivacaine, etc.

The active ingredients that can be used in the active formulations that can be attached to the capsular implant that is the subject of the invention can be chosen from the group of any other active ingredient that can be used to treat a pathology of the eye (retinopathies, uveitis, various infections of the eye): diabetic retinopathies (tolrestat, lisinopril, enelapril, etc.), DNA therapy or geno-therapy compounds, immunotherapy compounds, nano-therapy compounds, polypeptides, etc.

[000110] The other elements that can be integrated in the capsular implant which is the subject of the invention are numerous.

[000111] It can be:

measuring and / or analyzing devices for collecting or transmitting any type of ocular data;

For example, chips, biochips, antennas, microprocessors, various biological event sensors, detectors for markers or factors in the context of pathologies such as AMD, retinal melanoma or uvea, intraocular pressure, detector of presence of atypical cells, as well as other devices derived from nanotechnologies, two-dimensional conductive metals such as graphene, silicene, etc.

control devices for the release of active ingredients. [000112] The capsular implant according to the invention can be used in a large number of situations, a non-limiting list is given below:

Postoperative management of lens surgeries (short term);

In this use, the capsular implant has, in addition to the active principle (s) administration properties, a mechanical compatibility with the capsular environment, allowing in particular the maintenance of the integrity of the capsular bag. It may also, in some cases, allow the stabilization of the walls of the capsular bag. The integrated active principles are those traditionally used during postoperative management (eye drops / injections).

Postoperative management of cataracts (medium / long term); It is possible to integrate active principles to avoid and / or delay secondary cataract or capsulose (such as 5-FU or methotrexate).

Management of other pathologies

It is possible to integrate active ingredients whose indication is the treatment of inflammatory diseases of the vitreous, inflammatory diseases of the retina, inflammatory disease of the anterior segment, macular edema (whatever their origin), the DM LA (age-related macular degeneration), chronic glaucoma, paroxysmal postoperative intraocular pressure surges in subjects at risk of cataract surgery or combined surgery: "corneal transplant + cataract" or "glaucoma + cataract, etc.

- Integration of other devices;

It is also possible to integrate certain devices, for example chips, biochips, antennas, microprocessors, various biological event sensors, detectors of markers or factors in the context of pathologies such as AMD, retinal or uveal melanoma, intraocular pressure sensors, atypical cell detector, and other nanotechnology devices, two-dimensional conductive metals such as graphene, silicene, etc.

[000113] All these uses can be cumulated.

It is important to specify that the positioning of the capsular implant according to the invention does not generate additional risks that are not included in the known and accepted risks of cataract surgery. As a result, the possibility of treating other pathologies and / or complications without additional infectious risk is a real asset. In some cases, the capsular implant can be used to treat conditions that do not require surgery of the lens. In the latter case, a lens surgery will be performed for the sole purpose of inserting the capsular implant to treat these conditions.

In order to illustrate the invention, FIGS. 1 to 13 are hereinafter described.

Figure 1: Sectional view of a semicircular capsular implant according to the invention Figure 1 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising four chambers 2a in the filiform body 6 of the implant 1. The chambers have openings 7 not closed. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. The largest dimension e of the section of said filiform body is shown. The walls 10 of said chambers 2 are shown.

Figure 2: Sectional view of a semicircular capsular implant according to the invention Figure 2 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising two open chambers 2b in the free ends of the implant 1. The chambers have openings 7 which are not closed, and the center distance taken in its smallest dimension z is shown. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. The filiform body 6 is shown. The largest dimension e of the section of said filiform body is shown. The walls 10 of said chambers 2 are shown.

Figure 3: Sectional view of a semicircular capsular implant according to the invention

3 shows a sectional view of a semicircular capsular implant 1 according to the invention comprising four chambers 2a in the filiform body 6 of the implant 1 and two chambers 2b in the free ends of the implant 1, and two transition zones 4. Said chambers 2a and 2b have unclosed openings 7, and the inter-axis taken in its smallest dimension z is shown for the chambers 2b. The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. The largest dimension e of the section of said filiform body is shown. The walls 10 of said chambers 2 are shown. Figure 4: External view of a semicircular capsular implant according to the invention

FIG. 4 represents an external view of a semicircular capsular implant 1 according to the invention comprising two gripping zones 3. The peripheral surface 5 is represented, as is the filiform body 6.

Figure 5: External view of a semicircular capsular implant according to the invention Figure 5 shows an external view of a semicircular capsular implant 1 according to the invention comprising four open and non-closed chambers 2a in the filiform body 6 of the implant 1, two chambers 2b open in the free ends of the implant 1 and two gripping zones 3. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5 , are represented.

Figure 5A shows a detailed view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown.

Figure 5B shows a detail view of an opening 7 of an open and non-closed chamber 2a in the filiform body 6 of the implant 1. One of the two gripping means 3 is shown.

FIG. 6: Sectional view of a semicircular capsular implant according to the invention in an injector cannula FIG. 6 represents a sectional view of a semicircular capsular implant 1 according to the invention comprising four open chambers 2a and non-closed in the filiform body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant 1, the capsular implant 1 being inserted into an injector cannula. The largest dimension e of the section of said filiform body is shown.

Figure 7: Sectional view of a semicircular capsular implant according to the invention

FIG. 7 represents a sectional view of a semicircular capsular implant 1 according to the invention comprising two open and non-closed chambers 2a in filiform body 6 of implant 1 as well as two open and non-closed chambers 2b. in the free ends of the implant 1. The openings 7 of the chambers 2a and 2b are shown. The outer circle arc x and the arc of inner circle are represented. The largest dimension e of the section of said filiform body is shown. The walls 10 of said chambers 2 are shown. Figure 8: External view of a semicircular capsular implant according to the invention

FIG. 8 represents an external view of a semicircular capsular implant 1 according to the invention comprising four open and non-closed chambers 2c of the filiform body 6 of the implant 1, two open and non-closed chambers 2b in the free ends of the implant 1 and two gripping zones 3. The outer circular arc x and the inner circular arc y, defined by the peripheral surface 5, are represented.

Figure 8A shows a detail view of one of the two free ends of the implant 1. An open chamber 2b is present in the free end of the implant 1 shown.

Figure 8B shows a detail view of an open and non-closed surface chamber 2c of filiform body 6 of implant 1. One of the two gripping means 3 is shown.

FIG. 8C represents a detailed view of an open and non-closed surface chamber 2c of the filiform body 6 of the implant 1.

Figure 9: External view of a semicircular capsular implant according to the invention

FIG. 9 represents an external view of a semicircular capsular implant 1 according to the invention comprising several open and non-closed chambers 2a in the filiform body 6 of the implant 1, and separated by partitions 9. The chambers 2a extend over almost the entire length of the implant 1. The chambers 2a have openings 7 unclosed. The walls 10 of said chambers 2 are shown.

Figure 9A shows a sectional view along the axis AA '. It shows a chamber 2a, and its opening 7. The inter-axis taken in its smallest dimension z is shown. The largest dimension e of the section of said filiform body is shown.

Figure 9B shows a schematic detail view of the peripheral surface of an end of the implant, showing a chamber 2a. Figure 10: External view of a semicircular capsular implant according to the invention

FIG. 10 represents an external view of a semicircular capsular implant 1 according to the invention comprising several open and non-closed chambers 2a in filiform body 6 of implant 1. Open and non-closed chambers 2a extend over almost the entire length of the implant 1, and are separated by partitions 9. The chambers 2a have openings 7 not closed. Unlike Figure 9, the section of filiform body 6 is not round but rectangular.

Figure 10A shows a sectional view along the axis AA '. It shows a chamber 2a, and its opening 7. The inter-axis taken in its smallest dimension z is shown. The largest dimension e of the section of said filiform body is shown. The walls 10 of said chambers 2 are shown. Figure 10B shows a schematic detail view of the peripheral surface of an end of the implant, showing a chamber 2a.

FIG. 11: External view of a semicircular capsular implant according to the invention FIG. 11 represents an external view of a semicircular capsular implant 1 according to the invention comprising several open and non-closed chambers 2a in the filiform body 6 of the implant 1. The open and non-closed chambers 2a extend over a portion of the length of the implant 1, and are separated by partitions 9. The chambers 2a have openings 7 that are not closed.

Figure 11A shows a sectional view along the axis AA '. It shows a chamber 2a, and its opening 7. The inter-axis taken in its smallest dimension z is shown. The armature 8 of the capsular implant 1 is also shown. The largest dimension e of the section of said filiform body is shown.

Figure 11B shows a schematic side view of the peripheral surface of an end of the implant.

Figure 12: Sectional view of a semicircular capsular implant according to the invention

Figure 12 shows a sectional view of a semicircular capsular implant 1 according to the invention. In this particular embodiment, the implant 1 has walls 10 having a honeycomb structure. More precisely, the form cells are hexagonal, and thus the structure of the walls 10 of the implant 1 is in "honeycomb". This structure of the walls 10 of the implant 1 "honeycomb" shows a plurality of non-closed chamber openings 7 along the inner arc of circle y. It is noted that other openings are present, other than along the inner arc of the circle y. The filiform body 6 is shown.

Figure 13: View of a semicircular capsular implant according to the invention

Figure 13 shows a view of a semicircular capsular implant 1 according to the invention.

In the right part, the view is a sectional view of a semicircular capsular implant 1 according to the invention. In contrast to Figure 12, it is not the walls of the implant that are "honeycomb", but the inside of the latter. On this right part, two chambers 2a are visible in the filiform body 6 of the implant 1 and a chamber 2b in a free end of the implant 1. Said chambers 2a and 2b have openings 7 which are not closed, and the inter-axis taken in its smallest dimension z is represented for the chambers 2b.

In the left part, the view is an external view of a semicircular capsular implant 1 according to the invention. In this part, the same rooms as in the right part exist, but are not visible in the figure. On the other hand, the peripheral surface 5 is visible.

The outer circle arc x and the inner circle arc y, defined by the peripheral surface 5, are shown. The largest dimension e of the section of said filiform body is shown. The term "capsular implant" means an implant intended to be inserted into the capsular bag, which can adopt any shape, the only limitation regarding the form is that the capsular implant should not interfere with the view.

[000117] The term "open and non-closed chamber" means a zone of volume, shape and variable geometry, in which the material constituting the implant is emptied, or molded, to the desired shape, in order to leave the place for various elements: active formulations in solid form (or in any other form) and / or analysis or measurement device and / or a device for controlling the release of active principle (s). We can distinguish several types of chambers: the open and non-closed chambers of the thread-like body of the implant, the open and non-closed chambers in the filiform body of the implant (the first being shallower than the second), the open chambers and non-closed in the free end of the implant (when the latter is open). In one embodiment, the implant has a plurality of open and non-closed chambers in the filamentary body of the implant, these chambers extending over almost the entire length of the implant. In the latter case, these rooms are separated by partitions or areas without rooms. An open and non-closed chamber allows to fix mechanically:

one or more active formulation (s), said active formulation (s) being released progressively into the capsular bag; then in all intraocular spaces by diffusion. AND OR

- one or more measurement and / or analysis device (s) for collecting or transmitting any type of ocular data;

For example chips, biochips, antennas, microprocessors, various biological event sensors, detectors of markers or factors in the context of pathology such as AMD, retinal melanoma or uvea, intraocular pressure, presence of atypical cells, other devices derived from nanotechnologies, two-dimensional conductive metals such as graphene, silicene etc. It may be for example sensors as described in the application WO 2014/058965 in the name of ALCON previously mentioned.

AND OR

one or more control device (s) for the release of active principle (s);

The chambers have no projection or asperity with respect to the surface of the implant.

[000119] The active formulation (s) and / or the measuring and / or analysis device (s), when they are attached, have no protrusion or roughness with respect to the surface of the implant.

[000120] Generally, the formulation (s) active (s) in solid form (or in any other form) and / or device (s) analysis or measurement and / or device (s) control of the release active principle (s) do not project beyond the peripheral surface of the implant, that is to say it (s) does not "exceed (s)" not the opening the chamber once inserted into the latter. Wherever the rooms are not open, they are defined by what are called "chamber walls".

[000122] "Partition" is understood to mean a particular chamber wall. This is a means of isolation from each other of the various open and non-closed chambers in the filiform body of the implant, when the latter are separated only by said partition. The material constituting the septum may be identical to or different from that (those) of the capsular implant. The septum is exclusively found in the embodiments in which the capsular implant comprises a succession of open and non-closed chambers of the same shape in the filiform body of the implant. For example, the partition may have a thickness of 0.2 to 2 mm, or more or less.

The term "non-closed opening of the chamber" means the communication zone between the chamber and the outside of the chamber. This is an area of variable geometry, having an area (light) compatible with the release of active ingredient, as well as with the establishment and maintenance of the various elements that can be incorporated in the chamber (active formulation, device analysis or measuring device, control device for the release of active principle (s), etc.) This non-closed opening is not blocked by the installation or addition of additional material, such as a film, porous or not, perforated or not, or a membrane as described in the prior art, it is therefore defined as an integral part of the chamber.

[000124] "Fixing means" means a means for mechanically fixing:

an active formulation, said active formulation being gradually released into the capsular bag; then in all intraocular spaces by diffusion.

AND OR

For example chips, biochips, antennas, microprocessors, various biological event sensors, detectors of markers or factors in the context of pathology such as AMD, retinal melanoma or uvea, intraocular pressure, presence of atypical cells, other devices derived from nanotechnologies, etc. It may be, for example, sensors as described in application WO 2014/058965 in the name of

ALCON previously cited.

AND OR

control devices for the release of active principles; [000125] Said means being a chamber created by recess or by molding of the capsular implant. The fixing means fixes the active formulation or the other integrable element by a mechanical action and / or any other means: glues, etc.

The term "active formulation" any formulation comprising at least one active ingredient, in solid form, pasty, gel or even liquid.

[000127] "Analysis or measurement device and / or a device for controlling the release of active principle (s)" means any device whose placement in the capsular bag is of any interest and whose size allows placement in / on the capsular implant object of the invention.

The term "impregnation" means the method of penetrating into the material (s) of the capsular implant one or more active principle (s).

[000129] The term "open capsular implant" any non-continuous capsular implant and having two free ends.

[000130] The term "filiform body of the capsular implant" means the areas of the capsular implant not being the two free ends. The two free ends are present only when the implant is open (and therefore open circular or semicircular or open pseudo-circular). The filiform body has a peripheral surface that defines at least one outer circular arc and an inner circular arc along the filiform body. The open and unclosed chambers are disposed on the peripheral surface of the filiform body along the inner arc.

The term "active formulation coating material" any material disposed between the active formulation and the outside of the active formulation. The coating, which is biodegradable or non-biodegradable, may play a role in the release of active ingredient (s). He may in particular limit, postpone their release. This is a means of controlling the release of active principle (s).

The term "peripheral surface of the filiform body" means the surface of the filamentary body of the implant being in contact with the outside. It forms a set of arcs of circle (variable angle according to the shape of the implant) of different diameters. The circular arc with the largest diameter is called the "outer circle arc", and the arc with the smaller diameter is called the "inner circle arc". When the implant is implanted in the capsular bag, the inner circular arc is the one generally farthest from the walls of the capsular bag. [000133] The term "circular capsular implant" means a capsular implant having a circular shape, having an arc of 360 °.

[000134] "Semicircular capsular implant" means a capsular implant having a semicircular shape. In one embodiment, the semicircular capsular implant has an arc of between 45 and 360 °. In one embodiment, the semicircular capsular implant has an arc of about 160 °, 180 °, 200 °, 220 °, 240 °, 260 °, 280 °, 300 °, 320 °, 340 °, 359 ° etc. In one embodiment, the semicircular capsular implant has an arc of about 240 °. In one embodiment, the semicircular capsular implant has an arc of about 340 °.

The term "capsular pseudo-circular implant" means a capsular implant having a pseudo-circular shape, that is to say ovoid, or even polygonal with a number of side greater than a certain number, for example greater than at 5 (hexagonal, heptagonal, octagonal, etc.). The implant may also have an asymmetrical shape with different radii of curvature, as for example in the application WO 01/35868 in the name of CORNEAL.

The term "capsula ire implant section / filiform body of the capsular implant" means the shape of the section of the implant in an area in which the implant is full. The section may be of any compatible geometric shape: round, trigonal, tetragonal (square, rectangular), pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8. The shape of the section of the implant can be chosen according to its ability to stop / limit the migration of cells (this migration may cause secondary cataract), it can for example be a form ca rre / recta ngu I is currently recounted in In the field of ophthalmology, the term "square edges" has a square section.

[000137] The term "gripping zone" means an area allowing the capsular implant to be grasped and accurately moved by an ophthalmic forceps or any other instrument used in ophthalmic surgery, this gripping area can be used to finish positioning the capsular implant in the bag, but may also, when the capsular implant has an open circular or semicircular or pseudo-circular structure, serve to rotate the capsular implant in the capsular bag to arrange it adequate. The grasping zone consists of thinning and / or thickening, the geometric shape of which will assist in grasping by any type of surgical instrument used in the eye. The gripping zone can also be an absence of material (we will call this zone a "digging zone"), whatever its geometrical shape, which could be used to the mobilization of the capsular implant by a hook or other instrument or cannula without this being a real prehension. Any type of gripping area and / or mobilization of the capsular implant so as to position and / or mobilize and / or rotate may adopt any type of geometric shape on the capsular implant as far as they respect the integrity of the capsular bag during the insertion of this same capsular implant in the capsular bag. For example, in the case where the capsular implant has an open circular or semi-circular or pseudo-circular shape, the gripping zone can help position the recesses upwards in order to oppose the gravity.

The term "transition zone of the capsular implant" means a zone having different mechanical properties that can be used to optimize the flexion, the flexibility, the elasticity of the capsular implant to facilitate its insertion into the capsular bag. These different mechanical properties are obtained either by an absence of material or by a different material. Areas that have been recessed as previously defined are explicitly excluded from the definition of "transition zones". These transition zones can be absent, unique or multiple.

The term "active ingredient release" means any transfer of active principle from the active formulation contained in the capsular implant to the external medium, in the specific case in the capsular bag and by diffusion from the latter.

The term "wall of the capsular bag" the wall of the envelope surrounding the lens, it is an ultrafine envelope.

The term "reinforcement of the capsular implant" means a reinforcement made of a material having a greater rigidity than that of at least one material of said capsular implant. The capsular implant frame has a section that can be of any geometric shape: round, trigonal, tetragonal (square, rectangular), pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8. In one embodiment, this reinforcement is made of at least PMMA (poly (methyl methacrylate)). The armature may extend the entire length of the capsular implant, or only over a portion of the length of the capsular implant. The armature may be present regardless of the shape of the section of the capsular implant.

By "direct contact" is meant a contact without medium or intermediate body between the formulations and / or devices and the middle of the capsular bag; for example without the presence of film and / or membrane. The chamber has a so-called non-closed opening. The capsular implant object of the invention may be made of any biologically compatible material.

The capsular implant object of the invention may consist of a material composed of at least one polymer.

In one embodiment, the polymer is chosen from acrylic polymers chosen from the group comprising PMMA (poly (methyl methacrylate)), HPMA (hydroxypropyl methacrylate), MMA (methyl methacrylate), BMA (butyl). methacrylate), HMA (hexyl methacrylate), LMA (lauryl methacrylate), HEMA (polyhydroxyethylmethacrylate), PEMA (poly (ethyl methacrylate)) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinked or uncrosslinked.

In one embodiment, the polymer is chosen from hydrophilic acrylic polymers.

[000147] In one embodiment, the polymer is chosen from hydrophobic acrylic polymers.

In one embodiment, the polymer is chosen from vinyl polymers chosen from the group comprising copolymers of polyvinyl alcohol (PVA), vinyl acetate-ethylene (EVA) and / or copolymers of these polymers. polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable.

In one embodiment, the polymer is chosen from silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, the polymers being able to be crosslinked or non-crosslinked.

In one embodiment, the polymer is chosen from the other polymers chosen from the group comprising polysulfone hair fibers, PEEK (polyether ether ketone), PAEK (polyaryl ether ketone), polyetherimide and polyimide. polyethers, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked. These polymers will be hereinafter called "other polymers".

In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or their mixtures, the polymers being crosslinked or uncrosslinked.

In one embodiment, the capsular implant according to the invention consists of assembling structures, each structure having polymers of different types and / or polymers of different molecular mass and / or polymers having different crosslinking. [000153] In one embodiment, the capsular implant is constituted by assembling structures, one of the structures of which is made of silicone polymer, said structure made of silicone polymer being at least partly in contact with the walls of the bag. capsular.

In one embodiment, the capsular implant is constituted by assembly of structures, one of the structures is made of silicone polymer, said structure made of silicone polymer being the only one in contact with the walls of the capsular bag.

Indeed, silicone polymers are particularly useful for fighting against secondary cataracts, they are also recognized by the FDA as such.

In one embodiment, the capsular implant is constituted by a structure assembly, at least one of which constitutes an armature or core of the capsular implant.

In one embodiment, the armature or core consists of at least one rigid polymer such as PMMA (poly (methyl methacrylate)).

In one embodiment, the capsular implant is formed of several portions of variable compositions, such as, for example, rigid PMMA segments and more flexible HEMA-MMA copolymer segments, this is notably described in the EP patent. 1,696,832 to MORCH ER GMBH.

In one embodiment, in order to limit the cellular adhesion and therefore the inflammatory reactions, the capsular implant which is the subject of the invention is treated (by impregnation, grafting and / or any other surface treatment) with certain other compounds, such as fluorinated derivatives or even polysaccharides: heparin and derivatives, hyaluronic acid, sulfated polysaccharides, etc.

In one embodiment, the capsular implant that is the subject of the invention is treated with fluorinated derivatives.

In one embodiment, the capsular implant that is the subject of the invention is treated with heparin or its derivatives.

In one embodiment, the capsular implant that is the subject of the invention is treated with hyaluronic acid.

In one embodiment, the capsular implant that is the subject of the invention is treated with a sulphated polysaccharide.

The capsular implant object of the invention may further be treated (by impregnation, grafting and / or any other surface treatment) with one or more active principle (s). It can be active principles mentioned above, or other active ingredients. The active formulations that can be integrated in / on the capsular implant which is the subject of the invention are very numerous.

The formulations may be biodegradable or non-biodegradable.

In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of polylactic / polyglycolic polymers comprising PLA (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PGLC (poly (glycolide-co-lactide-co-caprolactone)) and / or copolymers of these polymers and / or mixtures thereof, the polymers being be crosslinked or uncrosslinked.

In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of vinyl polymers including PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), polyvinylpyrrolidones and or the copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or non-crosslinked.

In one embodiment, the active formulations comprise, in addition to the active principle, at least one polymer selected from the group of polysaccharides comprising hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose and keratane. , dextran, heparin, polyalditol, pentosan, starch and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked.

In one embodiment, the active formulations comprise, in addition to the active ingredient, at least one polymer selected from the group of other formulation polymers comprising PEG (polyethylene glycol), PCL (polycaprolactone), polyanhydrides, silicone carbide, polysulfone, POE (poly (orthoesters)), polyanhydrides, polyamines, polyurethane, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly ( malic acid), the poly (amino acids), the poly-tyrosine polymers, the poloxamer and / or the copolymers of these polymers and / or their mixtures, the polymers being able to be crosslinked or non-crosslinked. These polymers will be hereinafter called "other formulation polymers".

In one embodiment, the polymers are selected from the group comprising polylactic / polyglycolic polymers, vinyl polymers, polysaccharides, other polymer formulations and / or copolymers of these polymers and / or mixtures thereof, polymers that can be crosslinked or uncrosslinked. [000172] The active formulations may be in any form having various rheological properties, thus having particular in solid forms, liquid, pasty, gels, etc., adapted to the open and non-closed chamber.

In one embodiment, the capsular implant according to the invention is characterized in that at least one active formulation having a variable viscosity, ductility and rigidity.

[000174] They can be biodegradable or non-biodegradable.

[000175] The active formulations that can be incorporated into the capsular implant that is the subject of the invention must be chosen according to:

the desired treatment (choice of the active principle (s));

the duration of the desired treatment;

the period chosen for such treatment (beginning of immediate or deferred release).

For example, a capsular implant according to the invention may comprise the following formulations:

active formulation 1: a formulated antibiotic, e.g. cefuroxime, the formulation allowing release for about 7 days, and starting immediately after implantation;

active formulation 2: a formulated anti-inflammatory, for example triamcinolone, the formulation allowing a release for about 30 days, and starting immediately after implantation;

active formulation 3: an anti-cancer formulated, for example 5-FU, the formulation allowing a programmed release, and beginning 2 to 3 months after implantation;

other device: an eye pressure sensor.

This example of capsular implant will allow antibiotic / anti-inflammatory treatment useful in the context of management after lens surgery. The release, in the medium term, of anticancer will prevent and / or treat a possible secondary cataract. Finally, the regular measurement of the eye pressure, as well as its transmission without any invasive step, will facilitate the management, in parallel, of glaucoma.

[000178] The invention relates to a capsular implant 1 characterized in that it comprises a filiform body 6 having a plurality of contiguous segments, the filiform body 6 having a peripheral surface 5 which defines at least one outer arc x along the length of the filiform body 6 and at least one inner circular arc y along the filiform body 6, the filiform body 6 comprising at least one open and non-closed chamber 2 of an active formulation and / or an analysis device or measuring and / or release control device of active principle (s), said open and non-closed chamber 2 being disposed on the peripheral surface 5 of said filiform body 6 along said inner circle arc y.

The invention relates to a capsular implant 1 characterized in that it comprises a filiform body 6 having a plurality of contiguous segments, the filiform body 6 having a peripheral surface 5 which defines at least one outer arc x along the length of the filiform body 6 and at least one inner circular arc y along the filiform body 6, the filiform body 6 comprising at least one open and non-closed chamber 2 of an active formulation and / or an analysis device or measurement and / or a device for controlling the release of active principle (s), said open and non-closed chamber 2 being disposed on the peripheral surface 5 of said filiform body 6 along said circular arc inner y, and allowing direct contact between said formulation and / or the one or more devices and the capsular medium.

[000180] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises an open and non-closed chamber 2.

[000181] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises two or more open and non-closed chambers 2.

[000182] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises three open and non-closed chambers 2.

[000183] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises four open and non-closed chambers 2.

[000184] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises five open and non-closed chambers 2.

[000185] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises six open and non-closed chambers 2.

In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is circular, open circular, semicircular, pseudo-circular or pseudo-circular open.

In one embodiment, at least one open and non-closed chamber 2 is an open and non-closed chamber in and / or on the surface of said filiform body 6.

In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is open circular, semicircular or pseudo-circular open.

In one embodiment, the capsular implant 1 according to the invention is characterized in that its shape is semicircular. In one embodiment, at least one open and non-closed chamber is chosen from the following forms: chamber 2a of said filamentary body 6, chamber 2c at the surface of said filiform body 6, chamber 2b in at least one of the free ends of the implant 1.

In one embodiment, at least one open chamber 2b is not closed in at least one of the free ends of the implant 1 has a cylindrical shape.

[000192] In one embodiment, the implant 1 comprises an open chamber 2b is not closed in each free end of the implant 1, said chambers having a cylindrical shape.

In one embodiment, the non-closed opening 7 of at least one chamber has a spacing taken in its smallest dimension z between 0.01 and 1.5 mm.

[000194] In one embodiment, the non-closed opening 7 of at least one chamber has a spacing taken in its smallest dimension z between 0.01 and 1 mm.

In one embodiment, the non-closed opening 7 consists of a plurality of openings, for example holes of a diameter between

0, 1 and 0.5 mm, preferably between 0.2 mm and 0.4 mm.

In one embodiment, the largest dimension of the section of said filamentary body 6 of said implant 1 is between 0, 1 and 3 mm.

In one embodiment, the largest dimension of the section of said filamentary body 6 of said implant 1 is between 1 and 2 mm.

[000198] In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 has a larger dimension of between 0.6 and 1.8 mm.

[000199] In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 has a larger dimension of between 1 and 1.4 mm.

In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 has a larger dimension of about 1.2 mm.

In one embodiment, the ratio between the spacing of the opening 7 taken in its smallest dimension z and the largest dimension of the section e of said filiform body 6 of said implant 1 is between 0, 1 and 0.9.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round shape with a diameter of between 0, 1 and 3 mm. In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round shape with a diameter of between 1 and 2 mm.

In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round shape with a diameter of between 0.6 and 1.8 mm.

In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round shape with a diameter of between 1 and 1.4 mm.

In a particularly preferred embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is round in shape with a diameter of about 1.2 mm.

In one embodiment, at least one open and non-closed chamber 2 is an open and non-closed chamber 2b made in one of the two free ends of said capsular implant 1.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of a honeycomb structure.

[000208] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, constituted by an internal cellular structure, the shape of said cells being chosen from the group consisting of round, trigonal, tetragonal, pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8, as well as their associations.

[000209] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an internal cellular structure, the shape of said cells being round.

[000210] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an internal cellular structure, the shape of said cells being trigonal.

[000211] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an internal cellular structure, the shape of said cells being tetragonal.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an inner cellular structure, the shape of said cells being pentagonal.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an inner cellular structure, the shape of said cells being hexagonal. When the shape of the cells is hexagonal, one can also speak of honeycomb internal honeycomb structure.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is, at least in part, made of an internal cellular structure, the shape of said cells being heptagonal.

[000215] In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, made of a honeycomb structure.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, constituted by a cellular structure, the shape of said cells being chosen from FIGS. the group consisting of round, trigonal, tetragonal, pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8, as well as their associations.

[000217] In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, made of a cellular structure, the shape of said cells being round.

[000218] In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, constituted by a cellular structure, the shape of said cells being trigonal.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, made of a honeycomb structure, the shape of said cells being tetragonal.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, made of a honeycomb structure, the shape of said cells being pentagonal.

[000221] In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, made of a cellular structure, the shape of said cells being hexagonal.

When the shape of the cells of the walls 10 of said chambers 2 is hexagonal, one can also speak of alveolar structure in "honeycomb".

In one embodiment, the capsular implant 1 according to the invention is characterized in that the walls 10 of said chambers 2 are, at least in part, consisting of a honeycomb structure, the shape of said cells being heptagonal.

[000224] In one embodiment, the capsular implant 1 according to the invention is characterized in that it consists of a material composed of at least one polymer.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from acrylic polymers chosen from the group comprising PMMA (poly (methyl methacrylate)), HPMA (hydroxypropyl) and methacrylate), MMA (methyl methacrylate), BMA (butyl methacrylate), HMA (hexyl methacrylate), LMA (lauryl methacrylate), HMEA (polyhydroxyethylmethacrylate), PEMA (poly (ethyl methacrylate)) and / or In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or their mixtures. the polymers may be crosslinked or uncrosslinked.

In one embodiment, the polymer is chosen from hydrophilic acrylic polymers.

[000227] In one embodiment, the polymer is chosen from hydrophobic acrylic polymers.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from vinyl polymers chosen from the group comprising polyvinyl alcohol (PVA) copolymers, acetate vinyl ethylene (EVA) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or uncrosslinked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, polymers may be crosslinked or uncrosslinked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the polymer is chosen from the other polymers chosen from the group comprising polysulfone capillary fibers, PEEK (polyether ether ketone), PAEK (polyaryl ether ketone), polyetherimide, polyimide, polyesters, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked. These polymers will be hereinafter called "other polymers". In one embodiment, the polymer is chosen from acrylic polymers, vinyl polymers, silicone polymers, siloxanes, the other polymers and / or copolymers of these polymers and / or their mixtures, the polymers being crosslinked or uncrosslinked.

In one embodiment, the capsular implant according to the invention consists of assembling structures, each structure having polymers of different types and / or polymers of different molecular mass and / or polymers having different crosslinking.

In one embodiment, the capsular implant is formed of several portions of variable composition, such as, for example, rigid PMMA segments and more flexible HEMA-MMA copolymer segments.

[000234] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises (n) chamber (s) open (s) and not closed (s) 2, (m) formulation (s) active (s) and (p) device (s) for analysis and control such as (m) + (p) <(n).

[000235] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is between 3 and 6, (m) is between 1 and 4, (p) is between 0 and 2.

[000236] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is between 3 and 6, (m) is between 1 and 4, (p) is between 1 and and 2.

[000237] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 3, (m) is equal to 1, (p) is between 0 and 2.

[000238] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 4, (m) is equal to 2, (p) is between 0 and 2.

[000239] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 5, (m) is equal to 3, (p) is between 0 and 2.

[000240] In one embodiment, the capsular implant 1 according to the invention is characterized in that (n) is equal to 6, (m) is equal to 4, (p) is between 0 and 2.

[000241] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one active formulation and / or at least one analysis or measurement device and / or at least one control device for the release of active principle (s).

In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one active formulation and / or at least one an analysis or measurement device and / or at least one device for controlling the release of active principle (s) which does not project (s) beyond the peripheral surface of said implant 1.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics, anti-inflammatories and anti-glaucoma drugs. , anti-cancer drugs, active principles used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active ingredient that can be used to treat a pathology of the eye ( retinopathies, uveitis, various infections of the eye).

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient selected from the group of steroidal or nonsteroidal anti-inflammatory drugs.

[000245] In one embodiment, the anti-inflammatory is cefuroxime.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anti-glaucomatous agents.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anticancer agents.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of active principles used in the treatment of AMD. .

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of immunosuppressants.

[000250] In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the antiviral groups.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the antifungal groups. In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antiallergics.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of anesthetics.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of any other active ingredient that can be used to treat a pathology of the eye (retinopathies, uveitis, various infections of the eye).

In one embodiment, the capsular implant 1 according to the invention is characterized in that the at least one active formulation comprises at least one active ingredient chosen from the groups of antibiotics and / or anti-inflammatories.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least two active formulations, said active formulations comprising respectively at least one active ingredient chosen from the group of antibiotics and at least one active ingredient selected from the group of anti-inflammatories.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it further comprises at least a third active formulation comprising at least one active ingredient selected from the group of anticancer agents.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in solid, liquid, pasty form, or in gel form.

[000259] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in solid form.

[000260] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in liquid form.

[000261] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in pasty form.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in gel form.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in a biodegradable or non-biodegradable solid form. [000264] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in biodegradable solid form.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation is in a non-biodegradable solid form.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer selected from the group consisting of PLA (acidic). polylactic), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PEG (polyethylene glycol), PCL (polycaprolactone), PGLC (poly (glycolide) co-lactide-co-caprolactone)) polyanhydrides, PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), silicone-carbide, polysulfone, POE (poly (orthoesters)), polysaccharides (hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratane, dextran, heparin, polyalditol, pentosan, starch, etc.), polyanhydrides, polyamines, polyurethanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), polyvinylpyrrolidones, poly (amino acids), poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer selected from the group of polylactic / polyglycolic polymers comprising PLA (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PGLC (poly (glycolide-co-lactide-co-caprolactone)) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of vinyl polymers comprising PVA. (polyvinyl alcohol), EVA (vinyl ethylene acetate), polyvinylpyrrolidones and / or copolymers of these polymers and / or mixtures thereof, the polymers may be crosslinked or non-crosslinked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer selected from the group of polysaccharides comprising hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratane, dextran, heparin, polyalditol, pentosan, starch and / or copolymers of these polymers and / or their mixtures, the polymers being crosslinkable or uncrosslinked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group of other formulation polymers comprising PEG (polyethylene glycol), PCL (polycaprolactone), polyanhydrides, silicone-carbide, polysulfone, POE (poly (orthoesters)), polyanhydrides, polyamines, polyurethanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), polyamino acids, poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or mixtures thereof, polymers that can be crosslinked or uncrosslinked. These polymers will be hereinafter called "other formulation polymers".

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one polymer chosen from the group comprising polylactic / polyglycolic polymers. , vinyl polymers, polysaccharides, other polymer formulations and / or copolymers of these polymers and / or mixtures thereof, the polymers may be crosslinked or uncrosslinked.

In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises, in addition to the active ingredient, at least one conductive polymer.

[000273] Conductive polymers are of particular interest in the field of the release of active principle. In particular, an external stimulus (eg electrical stimulation) is likely to modify their properties. Among the properties that can be modified, the release of active principle is particularly noteworthy.

Thus, by means of an electrical stimulation device that can be outside the eye, it is possible to modify the release of active principle depending on the patient, the severity of the case, etc.

The properties of the conductive polymers can therefore be used, for example to modulate the release of one or more active principle (s). [000276] A conductive polymer is an almost always organic polymer having a conductivity of at least 1 Ω ^ ατι ^"1 .

In one embodiment, the at least one conductive polymer is a conductive organic polymer.

[000278] In some embodiments, the conductive polymer has a conductivity of at least 10 cm ^_1 Q or at least 100 Ω ^ ατ or at least 500 Ω ^ ατΓ ^1, or at least 1000 fi 'cm ^"1.

[000279] The invention is not limited to any particular conductive polymer as long as the polymer has the properties described above.

[000280] A wide range of conductive polymers are known.

In some embodiments, the conductive polymer is selected from the group consisting of polyacetylenes, polypyrroles, polyanilines, polythiophenes, polyphenylenes, poly (3,4-ethylenedioxythiophene), poly (p-phenylene) vinylene), and / or the copolymers of these polymers and / or their mixtures or dispersions.

In some embodiments, the conductive polymer is a poly (3,4-ethylenedioxythiophene) (PEDOT) or a copolymer thereof or a dispersion.

In some of these embodiments, the conductive polymer is a dispersion of PEDOT and a polysulfonate, such as poly (p-styrene sulfonate (PSS)).

In some cases, these dispersions may be obtained commercially, it may for example be Orgacon EL P-3040®, Orgacon EL P-3145®, Orgacon IJ-1005®, etc.

In other embodiments, the conductive polymer is a dispersion of PEDOT and tetramethacrylate (TMA).

[000286] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least one active formulation comprises at least one coating material of active formulation.

[000287] In one embodiment, the capsular implant 1 according to the invention is characterized in that the coating material is any material.

[000288] In one embodiment, the capsular implant 1 according to the invention is characterized in that the coating material is a polymer.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the coating material of active formulation is chosen from the materials previously mentioned as being capable of entering the constitution of the invention. implant 1. [000290] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one analysis or measurement device and / or a control device for the release of principle (s). ) active (s).

[000291] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one analysis or measurement device.

[000292] In one embodiment, the at least one analysis or measurement device chosen from the group consisting of chips, biochips, antennas, microprocessors, various biological event sensors, marker detectors. or factors in the context of pathologies such as AMD, retinal melanoma or uvea, intraocular pressure sensors, atypical cell presence detector, as well as other devices derived from nanotechnologies, two-dimensional conductive metals such as graphene, silicene etc.

[000293] In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises at least one device for controlling the release of active principle (s).

[000294] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises one or at least two transition zones 4.

[000295] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises a transition zone 4.

[000296] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises at least two transition zones 4.

In one embodiment, in order to limit cell adhesion and therefore inflammatory reactions, the capsular implant 1 which is the subject of the invention is treated (by impregnation, grafting and / or any other surface treatment) with certain other compounds, for example fluorinated derivatives or even polysaccharides

[000298] In one embodiment, the capsular implant 1 which is the subject of the invention is treated with heparin or its derivatives.

[000299] In one embodiment, the capsular implant 1 which is the subject of the invention is treated with hyaluronic acid.

In one embodiment, the capsular implant 1 object of the invention is treated with a sulfated polysaccharide.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is furthermore treated with other compounds chosen from the group comprising heparin and derivatives, hyaluronic acid, fluorinated derivatives and / or sulphated polysaccharides.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds selected from the group comprising heparin and its derivatives.

[000303] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with hyaluronic acid.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds selected from the group comprising fluorinated derivatives.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is further treated with other compounds chosen from the group comprising sulphated polysaccharides.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round, trigonal, tetragonal, pentagonal, hexagonal, heptagonal, octagonal, or any other shape having a number of faces greater than 8.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of round or tetragonal shape.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is round, square or rectangular.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is round in shape.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of trigonal shape.

[000310] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of tetragonal shape.

[000311] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is square.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of rectangular shape.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of pentagonal shape. In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of hexagonal shape.

[000315] In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of heptagonal shape.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of octagonal shape.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the section of said filiform body 6 is of shape having a number of faces greater than 8.

[000318] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises one or at least two gripping zones 3.

[000319] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises a gripping zone 3.

[000320] In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises at least two gripping zones 3.

In one embodiment, the capsular implant 1 according to the invention is characterized in that the filiform body 6 comprises two gripping zones 3.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it comprises an armature or core 8 made of a material having greater rigidity than the rest of the material (s) of the implant 1.

In one embodiment, said armature or core 8 consists of at least PMMA (poly (methyl methacrylate)).

[000324] In one embodiment, the capsular implant 1 according to the invention is characterized in that at least two open and unclosed chambers 2 are open chambers 2a and not enclosed in the filiform body 6 of the implant 1, said chambers 2a being separated by a partition 9.

In one embodiment, said partition comprises at least one of the constituent material (s) of the capsular implant 1.

In one embodiment, said partition comprises at least one material different from the constituent material (s) of the capsular implant 1. In one embodiment, the capsular implant 1 according to the invention is characterized in that said implant is impregnated with one or more active principle (s).

In one embodiment, the capsular implant 1 according to the invention is used as part of a post-operative management of a lens surgery.

In one embodiment, the capsular implant 1 according to the invention is used in the context of a post-operative management of a lens surgery in humans.

In one embodiment, the capsular implant 1 according to the invention is used in the context of a post-operative management of a lens surgery in animals.

In one embodiment, the capsular implant 1 according to the invention is used in the context of a post-operative management of cataractous lens surgery.

In one embodiment, the capsular implant 1 according to the invention is used as part of a post-operative management of a clear lens surgery.

[000333] In one embodiment, the capsular implant 1 according to the invention is used in experimental ophthalmology.

In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used as part of a treatment for human cataract.

[000335] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used in the context of animal cataract treatment.

[000336] In one embodiment, the capsular implant 1 according to the invention is characterized in that it is used in experimental ophthalmology.

Claims

Capsular implant (1), characterized in that it comprises a filiform body (6) comprising a plurality of contiguous segments, the filiform body (6) having a peripheral surface (5) which defines at least one outer circular arc (x) along the filiform body (6) and at least one inner arc (y) along the filiform body (6), the filiform body (6) comprising at least one attachment means (2) of a active formulation and / or an analysis or measurement device and / or a device for controlling the release of active principle (s), said fixing means (2) being an open chamber and not -closed arranged:

on the peripheral surface (5) of said filiform body (6) along said inner circle arc (y); or

in one of the free ends of said implant (1);

and allowing direct contact between said formulation and / or said device (s) and the capsular medium.

2. capsular implant (1) according to any one of the preceding claims, characterized in that its shape is semicircular.

3. Capsular implant (1) according to any one of the preceding claims, characterized in that at least one open and non-closed chamber (2) is an open and non-closed chamber selected from the following forms: chamber (2a) ) of said filiform body (6), chamber (2c) at the surface of said filiform body (6), chamber (2b) in at least one of the free ends of the implant

(1).

4. capsular implant (1) according to any one of the preceding claims, characterized in that at least one open and non-closed chamber

(2) is a chamber (2b) in one of the two free ends of said capsular implant (1).

5. Capsular implant (1) according to any one of the preceding claims, characterized in that it consists of a material composed of at least one polymer.

6. capsular implant (1) according to claim 5, characterized in that the polymer is selected from acrylic polymers, vinyl polymers, silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, polymers that can be crosslinked or uncrosslinked.

7. Capsular implant (1) according to claim 5, characterized in that the polymer is chosen from vinyl polymers selected from the group comprising copolymers of polyvinyl alcohol (PVA), vinyl acetate-ethylene (EVA) and / or copolymers of these polymers and / or mixtures thereof, the polymers being crosslinkable or non-crosslinkable.

8. capsular implant (1) according to claim 5, characterized in that the polymer is selected from silicone polymers, siloxanes and / or copolymers of these polymers and / or mixtures thereof, the polymers may be crosslinked or uncrosslinked.

9. capsular implant (1) according to claim 5, characterized in that the polymer is selected from polymers selected from the group consisting of polysulfone hair fibers, PEEK (polyether ether ketone), PAEK (poly aryl ether ketone) polyetherimide, polyimide, polyesters, polypropylene, polycarbonates, nylons and / or copolymers of these polymers and / or mixtures thereof, the polymers being cross-linked or non-cross-linked.

10. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one active formulation.

11. capsular implant (1) according to claim 10, characterized in that the at least one active formulation comprises at least one active ingredient selected from the group of antibiotics, anti-inflammatories, anti-glaucoma, anti-cancerous , active ingredients used in the treatment of AMD, immunosuppressants, antivirals, antifungals, antiallergics, anesthetics and / or any other active ingredient that may be used to treat a pathology of the eye (retinopathies, uveitis, infections various of the eye).

12. Capsular implant (1) according to claim 10, characterized in that at least one active formulation comprises, in addition to the active ingredient, at least a polymer selected from the group consisting of PLA (polylactic acid), PLLA (L-polylactic acid), PGA (polyglycolic acid), PLGA (polylactic-co-glycolic acid), PEG (polyethylene glycol), PCL (polycaprolactone), PGLC (poly (glycolide-co-lactide-co-caprolactone)) polyanhydrides, PVA (polyvinyl alcohol), EVA (vinyl ethylene acetate), silicone-carbide, polysulfone, POE ( poly (orthoesters)), polysaccharides (hyaluronic acid, chitosan, chondroitin, maltodextrin, amylose, keratane, dextran, heparin, polyalditol, pentosan, starch, etc.), polyanhydrides, polyamines, polyuretane, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly (malic acid), polyvinylpyrrolidones, polyamino acids, poly-tyrosine polymers, poloxamer and / or copolymers of these polymers and / or their mixtures, the s polymers that can be crosslinked or uncrosslinked.

13. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one analysis or measurement device.

14. Capsular implant (1) according to any one of the preceding claims, characterized in that it comprises at least one device for controlling the release of active principle (s).

15. Use of a capsular implant (1) according to any one of claims 1 to 14 in the context of a post-operative management of a lens surgery in humans or animals.

16. Use of a capsular implant (1) according to any one of claims 1 to 14 in experimental ophthalmology.